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Abstract In previous studies, we reported that sphingosine 1-
phosphate (Sph-1-P) inhibits the chemotactic motility of some
cancer cell lines such as mouse melanoma cells, as well as human
smooth muscle cells, at a very low concentration, as demon-
strated by a transwell migration assay method (Proc. Natl. Acad.
Sci. USA 89, 9698, 1992; J. Cell Biol. 130, 193, 1995). In this
study, we investigated the effect of Sph-1-P on the chemotactic
motility and invasiveness of human neutrophils, utilizing three
different assay systems: (a) a transwell migration assay where
IL-8 or fLMP was added as a chemotactic factor, (b) a
phagokinetic assay with gold colloids, and (c) a trans-endothelial
migration assay with human umbilical vein endothelial cells
(HUVECs) plated on collagen layers. We found that among
various sphingosine derivatives, Sph-1-P specifically inhibited the
IL-8- or fLMP-induced chemotactic migration of neutrophils at
concentrations below 1 WM. Phagokinetic activity of neutrophils
was also suppressed by Sph-1-P, but more moderately than by
the PKC inhibitory sphingosine analog, trimethylsphingosine.
Finally, Sph-1-P inhibited trans-endothelial migration and
invasiveness of neutrophils into HUVEC-covered collagen layers,
whereas no effect on their adhesion to HUVECs was observed.
These observations strongly suggest that Sph-1-P can act as a
specific and effective motility regulator of human neutrophils,
raising the possibility of future applications of Sph-1-P, or its
analogs, as anti-inflammatory agents regulating invasive migra-
tion of neutrophils through endothelial layers at injured vascular
sites.
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1. Introduction
Sphingosine 1-phosphate (Sph-1-P), the initial product of
the catabolism of sphingosine by sphingosine kinase, had
once been regarded simply as an intermediary metabolite in
sphingolipid metabolism in cells [1]. However, recent studies
have shown that Sph-1-P has several important physiologic
functions other than its role as a metabolite of Sph. Although
originally proposed as a mitogenic messenger [2,3], Sph-1-P
has since been reported to be involved in a variety of cellular
functions, including activation of human platelets acting in an
autocrine manner [4,5], activation of muscarinic K current in
atrial myocytes [6], mediation of FcORI antigen receptor sig-
nalling [7], and neurite retraction [8,9].
In our previous studies, we also found that exogenously
added Sph-1-P inhibits the chemotactic motility of various
cancer cells as well as human smooth muscle cells [10,11] by
interfering with actin ¢lament reorganization in the leading
edges of pseudopodia stimulated by chemotactic factors [12].
Furthermore, very recently, we found that Sph-1-P inhibits
cell motility of melanoma cells by acting through its cell sur-
face receptors [13]. However, in these studies, the sensitivity
for Sph-1-P was very di¡erent among various cell types and
motility inhibition by Sph-1-P seemed a cell-type speci¢c phe-
nomenon [10]. Therefore, in the present study, we utilized
di¡erent in vitro assay systems to investigate whether Sph-1-
P can a¡ect the chemotactic motility and trans-endothelial
invasiveness of human neutrophils, fast migrating cells, the
trans-endothelial migration of which seems to be relevant to
the development of in£ammatory reactions in blood vessels.
2. Materials and methods
2.1. Chemicals
Sphingosine, trimethylsphingosine (TMS), C8-ceramide (N-octanoyl
sphingosine), sphingosine 1-phosphate (Sph-1-P), dihydro-Sph-1-P,
and [1-3H]Sph were prepared in this lab as previously described
[14^17]. Stock solutions of Sph-1-P and other sphingosine derivatives
(2 mM) were prepared in ethanol:water (1:1) solution, stored at
320‡C and sonicated for 30 s at room temperature just before use,
with appropriate dilution. Control experiments were performed with
ethanol (¢nal concentration, 6 0.5%) as a vehicle, which did not a¡ect
neutrophil functions. IL-8 and IL-1L were purchased from UBI (Lake
Plasid, NY), phorbol 12-myristate 13-acetate (PMA) was from Cal-
biochem (Indianapolis, IN). Other chemicals were reagent grade and
purchased from Sigma (St. Louis, MO).
2.2. Human neutrophils and other cells
Human neutrophils were isolated with Ficoll-Paque (Pharmacia
LKB, Uppsala, Sweden) centrifugation method, as previously de-
scribed [18]. The ¢nal preparation consisted of s 98% neutrophils,
as determined by Wright-Giemsa staining. Cell suspensions were
kept on ice and used within 3 h. Human umbilical vein endothelial
cells (HUVEC) and CS-C culture medium (acidic ¢broblast growth
factor and heparin supplemented) were obtained from Cell System
(Kirkland, WA), and cultured to monolayer on a collagen bed in
24-well culture plates as previously described [19,20].
2.3. Neutrophil myeloperoxidase assay
For quanti¢cation of neutrophil cell number, we measured the mye-
loperoxidase activity of neutrophils, as previously described [21].
Brie£y, neutrophils sedimented with light centrifugation were solubi-
lized in 10 Wl of 0.1% Triton-X 100 with sonication for 10 min. To this
lysate, 300 Wl o-dianisidine solution (10 mg o-dianisidine in 20 ml 0.05
M phosphate-citrate bu¡er, pH 5, containing 0.003% sodium perbo-
rate) was added, the color reaction was developed for 30 min, termi-
nated by the addition of 50 Wl 0.5 N HCl, and the OD405 was meas-
ured with reference at 630 nm. The linear relationship between the
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absorbance and cell counts was observed at the 1U104^1U105 cells.
This correlation was una¡ected under various medium conditions
used in this study, trypsin-EDTA, RPMI 1640, 1038 M fMLP, or
5 ng/ml IL-8.
2.4. Transmigration assay with HUVEC monolayer
Transmigration assay of neutrophils (1.6U106 cells) was performed
on IL-1L-stimulated HUVEC monolayer, as previously described [19].
After formaldehyde ¢xation, the collagen bed with surface HUVECs
and migrated neutrophils, was embedded in para⁄n, stained with
hematoxylin-eosin, and sliced for slide preparation. Photomicrographs
were taken for each slide (U100). For quanti¢cation of migrated cells,
cells in the collagen bed were counted per 100 Wm length of HUVEC
in pictures of 23 to 63 di¡erent ¢elds for each experiments.
2.5. Adhesion assay with HUVEC monolayer
Human neutrophil suspension (300 Wl, 1U106 cells/ml) in M199
with 1% heat-inactivated FCS was added on HUVEC monolayer,
prestimulated with IL-1L (10 U/ml) for 4 h, and incubated for 15
min at 37‡C. Non-adherent neutrophils were removed by gentle shak-
ing and aspiration. After the plates were washed with PBS, neutro-
phils attached on HUVEC were treated with 300 Wl trypsin-EDTA
solution, and detached cells were transferred to a microcentrifuge tube
and mixed with 100 Wl RPMI 1640 with 10% heat-inactivated FCS.
Adherent neutrophils were counted by measuring the myeloperoxidase
activity as described above. As a control, the enzyme activity of neu-
trophil attached to unstimulated HUVEC and that of HUVEC alone
was measured.
2.6. Chemotaxis assay with modi¢ed Boyden chamber
Neutrophil chemotaxis was measured using a transwell chamber
(Costar, Cambridge, MA) with 6.5 mm diameter polycarbonate ¢lters
(3 Wm pore size) as previously described [10]. Brie£y, human neutro-
phils (1U106 cells/ml) in RPMI 1640 with heat-inactivated FCS were
preincubated with test compounds for 10 min at 37‡C, and a 100 Wl
cell suspension was loaded into the upper chamber. 600 Wl of medium
containing a chemoattractant (5 ng/ml IL-8, or 1038 M fMLP) and a
test compound was loaded in the lower chamber. Then, the upper
chamber was combined to the lower chamber, and incubated at
37‡C for 30 min in a CO2 incubator. Migrated cells (those in the
lower chamber and attached to the lower surface of the ¢lter) were
trypsinized and counted by measuring myeloperoxidase activity.
2.7. Phagokinetic activity with gold colloid glass plates
Phagokinetic assays with gold colloid-coated plates were performed
as described [19,22]. Brie£y, fresh human neutrophils (4U103 cells/
plate) were seeded on gold colloid-coated coverslips, in RPMI 1640
with or without Sph derivatives, and incubated at 37‡C for 30 min in
a CO2 incubator. After formaldehyde ¢xation, the coverslips were
mounted onto glass microscope slides. The tracks of phagocytosis
were traced onto transparent sheets from a television monitor con-
nected to a microscope, and the areas of phagocytosis were calculated
by measuring the weight of photocopied tracks [10,19].
2.8. O2 consumption and O32 production
O2 consumption of neutrophils stimulated with PMA in the pres-
ence of Sph derivatives was performed using a Clark-type electrode
with a Model 5300 biological O2 monitor and micro O2 chamber
(Y.S.I. Inc. Yellow Springs, OH), as recently described [19]. O32 pro-
duction was measured by monitoring O32 -mediated cytochrome C
reduction as described [19].
3. Results
3.1. Inhibition of chemotactic migration of neutrophils with
Boyden chamber
First, e¡ects of exogenously added Sph-1-P and other
sphingosine derivatives on human neutrophil migration were
examined utilizing a modi¢ed Boyden chamber with Costar
Transwell tissue culture plates. In this experiment, neutrophils
migrated into the lower chamber under the in£uences of neu-
trophil chemotactic factors, fLMP and IL-8 [23], and in the
presence or absence of tested compounds, were quanti¢ed by
measuring their myeloperoxidase activity. Under these exper-
imental conditions, spontaneous migration of neutrophils was
negligible. Addition of both fMLP (1038 M) or IL-8 (5 ng/ml)
stimulated chemotactic migration of neutrophils about 100-
fold. The fLMP- or IL-8-induced chemotaxis was signi¢cantly
inhibited at 0.5 WM or higher concentrations of added Sph-1-
P with about 50% of inhibitions being observed at the optimal
concentration, 1 WM (Fig. 1). A transient decrease of inhib-
ition was observed at 5 WM, as we reported previously in
melanoma experiments [10], but the underlying mechanism
for the U-shaped inhibition curves is not known. It should
be noted that viability of neutrophils remained similar from
controls up to 75 WM of Sph-1-P, by trypan-blue exclusion
assay. Therefore, these e¡ects were not due to cytotoxicity of
this compound even at the highest concentration. Inhibition
of neutrophil migration by Sph-1-P was very speci¢c among
various related sphingolipids. No other derivatives tested
(sphingosine, N-formylsphingosine, C8-ceramide, TMS)
showed any signi¢cant inhibitory e¡ect even at 1 WM concen-
tration (Table 1). Interestingly, a closely related analog (with-
out 4,5-double bond) of Sph-1-P, dihydro-Sph-1-P, was also
totally ine¡ective.
3.2. E¡ects on phagokinetic tracks of neutrophils and O32
formation
As shown in Table 2, Sph-1-P showed signi¢cant e¡ects on
phagokinetic activity of neutrophils, as measured by gold col-
loid assay, in a similar dose-dependent manner, although
TMS, a lipid PKC inhibitor, showed much stronger e¡ects
even at a lower concentration, as we already reported previ-
ously [19]. On the other hand, C8-ceramide did not show
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Fig. 1. Sph-1-P e¡ects on IL-8- and fMLP-induced neutrophil
chemotaxis with Boyden chamber. 100 Wl of human neutrophils
(1U106/ml) in RPMI 1640 supplemented with 1% heat-inactivated
FCS was preincubated with tested compounds for 10 min at 37‡C
and put into the upper chamber of a transwell assay system with a
3 mm pore size polycarbonate membrane. IL-8 (5 ng/ml) or fMLP
(1038 M), together with the lipid compounds in 600 Wl of the same
bu¡er was put into the lower chamber. After 30 min incubation, mi-
grated cells (in lower chamber media and detached cells from lower
surface of membrane with trypsin-EDTA) were collected, and cell
numbers were counted by myeloperoxidase measurement. In this as-
say system, spontaneous migration with bu¡er alone was negligible.
The data were mean þ S.D. of four independent experiments.
*P6 0.05, **P6 0.01.
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inhibition even at a higher concentration, 5 WM. These results
probably re£ect the facts that the gold colloid phagokinetic
assay method may measure mixed abilities of random cell
motility and phagocytosis [22], and that phagocytotoxic abil-
ity of neutrophils requires PKC activation [19]. Consistent
with these results, as we reported previously, PMA-induced
O32 formation in neutrophils was strongly inhibited by TMS
[19], whereas Sph-1-P as well as ceramide, which have no
PKC inhibitory activity, had no e¡ects on the formation of
O32 in PMA-activated neutrophils (data not shown).
3.3. Inhibition of in vitro trans-endothelial invasion of
neutrophils
To examine the e¡ects of Sph-1-P on trans-endothelial in-
vasion of human neutrophils, we utilized the experimental
system of a HUVEC monolayer plated on a collagen matrix,
roughly resembling the in vivo situation of transmigration of
neutrophils, through attachment to inactivated endothelial
cells, into the vascular matrix. In this experiment, human
neutrophils, plated on the IL-1L-activated (4 h preincubation)
HUVEC monolayer, attached to HUVECs and migrated into
the collagen matrix during 90 min incubation. As shown in
Fig. 2A and B, trans-endothelial migration (invasion) of neu-
trophils was signi¢cantly inhibited by pretreatment with 0.1^
1.0 WM Sph-1-P, and even more strongly suppressed by pre-
treatment with higher concentrations around 5^15 WM. Here,
the viability of both HUVEC and human neutrophils was not
a¡ected up to 75 WM. On the other hand, sphingosine or C8-
ceramide did not show any e¡ects under these conditions
(data not shown).
To exclude the possibility that Sph-1-P inhibited the migra-
tion through inhibiting neutrophil adhesion, we next exam-
ined the e¡ects of Sph-1-P on neutrophil adhesion to the
HUVEC monolayer. As shown in Fig. 3, IL-1L stimulated
neutrophil adhesion about 10-fold compared to unstimulated
control experiments, but no e¡ect of Sph-1-P pretreatment
was observed for this stimulation in concentrations of 0.1 to
5 WM. Therefore, the inhibitory e¡ect of Sph-1-P on neutro-
phil trans-endothelial migration is apparently not due to in-
hibiting the initial adhesion, indicating that Sph-1-P mainly
a¡ects the motility of neutrophils in the trans-endothelial in-
vasive migration processes.
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Fig. 2. Sph-1-P suppressed trans-endothelial migration of neutro-
phils. Human neutrophils in M199 medium supplemented with heat-
inactivated FCS were preincubated with test compounds for 10 min
at 37‡C. Neutrophil suspension was then added to HUVEC mono-
layer on collagen bed, which was prestimulated with 10 U/ml IL-1L
for 4 h. Culture plates were incubated further for 90 min at 37‡C,
then ¢xed with 10% formaldehyde, para⁄n-embedded, stained hem-
atoxylin-eosin. A: Representative pictures of para⁄n-embedded
samples at various Sph-1-P concentrations. B: Quanti¢cation of mi-
grated neutrophils, counted as invaded neutrophil numbers per 100
Wm length of HUVEC monolayer, and expressed as the percentage
of control. The data are mean þ S.D. (sample numbers). *P6 0.05,
**P6 0.01.
Table 2








None (control) 6.3 þ 2.3 141
Sph-1-P 0.5 WM 5.5 þ 2.7* 80
1.0 WM 5.4 þ 2.4* 74
5.0 WM 3.5 þ 1.4** 123
TMS 0.5 WM 5.4 þ 2.7* 77
1.0 WM 3.6 þ 1.4** 100
C8-ceramide 5.0 WM 5.7 þ 3.0 75
The data were mean þ S.D. (number of measurements).
*P6 0.05, **P6 0.01.
Table 1
E¡ects of Sph-1-P and other sphingosine derivatives on IL-8- and
fLMP-induced chemotactic migration in a Boyden chamber
Tested compound % of control
1 WM
IL-8 (1038 M) fMLP (5 ng/ml)
None (control) 100 þ 12 100 þ 23
Sph-1-P 46 þ 13** 54 þ 18**
dihydro-Sph-1-P 81 þ 18 93 þ 12
sphingosine 87 þ 8 90 þ 17
N-formylsphingosine 81 þ 14 88 þ 17
TMS 79 þ 29 90 þ 22
C8-ceramide 95 þ 12 92 þ 6
The data were mean þ S.D. of three independent experiments.
**P6 0.01.
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4. Discussion
Our previous studies showed that exogenously added Sph-
1-P inhibits the chemotactic motility of cancer cell lines, such
as mouse melanoma cells, as well as human smooth muscle
cells in in vitro experiments [10,11] by interfering the actin
¢lament reorganization in activated cells [12]. However, in
these previous studies we realized that the sensitivities for
Sph-1-P in motility regulation depends on cell type. For ex-
ample, the motilities of mouse melanoma cells and human
smooth muscle cells were very sensitive for this lipid, whereas
endothelial cells such as HUVEC and CPAE were much less
sensitive [10]. In this study, we investigated the e¡ect of Sph-1-
P on regulating chemotactic motility and invasiveness of hu-
man neutrophils, utilizing three di¡erent in vitro assay sys-
tems (chemotactic, phagokinetic, and trans-endothelial mod-
els). We found that (1) Sph-1-P, alone of the sphingolipids
tested, speci¢cally inhibited the IL-8- of fLMP-induced chem-
otactic migration of neutrophils at less than 1 WM concen-
tration; (2) phagokinetic activity of neutrophils was sup-
pressed by Sph-1-P, but more moderately than by the PKC
inhibitory sphingosine analog, trimethylsphingosine; (3) Sph-
1-P inhibited trans-endothelial migration and invasiveness of
neutrophils into HUVEC-covered collagen layers, whereas no
e¡ects on their adhesion to HUVEC was observed. These
observations strongly suggest that Sph-1-P can act as a spe-
ci¢c and e¡ective motility regulator of neutrophils.
The underlying mechanism for di¡erent sensitivities for
Sph-1-P among various cells is uncertain at present, but it
may relate to the expression of its receptor molecules on the
cell surface [13]. Indeed, in our preliminary experiments, the
strong speci¢c binding of [3H]Sph-1-P was observed on the
surface of human neutrophils. Sph-1-P may inhibit actin ¢la-
ment reorganization in leading edges of neutrophil pseudopo-
dia by acting through the cell surface receptor, thus resulting
in the observed inhibition of motility and trans-endothelial
migration.
We recently reported that Sph-1-P acts as an autocrine
stimulator of human platelets, being stored in platelets and
released extracellularly upon thrombin stimulation [4,5], and
also identi¢ed Sph-1-P as a normal constituent in human
plasma and serum [24]. These observation strongly suggest
that Sph-1-P may act not only as an exogenously added
tool for motility regulation but also acts as a physiological
cell motility regulator in blood vessels. This possibility seems
to be important especially when considering the roles of plate-
let-neutrophil-endothelial cell interaction in in£ammation de-
velopment [25].
The recruitment of circulating neutrophils to speci¢c sites
plays a crucial role in a number of physiological and patho-
physiological events including protection from microorgan-
isms and, on the contrary, development of in£ammatory proc-
esses. In case of in£ammation, circulating neutrophils ¢rst
attach to activated endothelial cells in blood vessels through
various induced adhesion molecules, then migrate through the
endothelial cell layer to injured sites, and, ¢nally, produce
toxic substances such as active oxygen species which may
destroy the surrounding tissues [26,27]. To prevent overreac-
tion of neutrophils in the injured sites, the processes consisting
of neutrophil adhesion, trans-endothelial migration, or even
the toxic substance production itself must be controlled prop-
erly [26,27]. Our present study raised the future applicability
of Sph-1-P, or an analog, as an anti-in£ammatory agent reg-
ulating invasion of neutrophils through endothelial layers at
vascular injured sites, working as an anti-motility factor. On
the other hand, in our previous studies we reported that ad-
ministration of one of sphingosine derivatives, TMS, e¡ec-
tively inhibited neutrophil adhesion to endothelial cells by
blocking P/E-selection expression on the endothelial cells
[28,29], and that TMS also inhibited PMA-induced O32 pro-
duction in neutrophils [19]. In both models, TMS seemed to
act by inhibiting cellular PKC activities in neutrophils or en-
dothelial cells as a cell permeable PKC inhibitor. The combi-
nation of TMS and Sph-1-P, which show totally distinct ef-
fects on neutrophils or endothelial cells, might be very
e¡ective in anti-in£ammation treatment, as indicated in cancer
metastasis prevention experiments in animals [30].
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